Sanofi-Aventis has won its second bellwether verdict over its chemotherapy drug Taxotere.

A federal jury came back with a defense verdict late Thursday night after two weeks of trial in New Orleans. The trial is the second bellwether from among nearly 12,500 lawsuits coordinated in multidistrict litigation alleging that women who take Taxotere, which is used to treat breast cancer, never grow back their hair. The first bellwether trial ended in a defense verdict in 2019.

This content has been archived. It is available through our partners, LexisNexis® and Bloomberg Law.

To view this content, please continue to their sites.

Not a Lexis Subscriber?
Subscribe Now

Not a Bloomberg Law Subscriber?
Subscribe Now

Why am I seeing this?

LexisNexis® and Bloomberg Law are third party online distributors of the broad collection of current and archived versions of ALM's legal news publications. LexisNexis® and Bloomberg Law customers are able to access and use ALM's content, including content from the National Law Journal, The American Lawyer, Legaltech News, The New York Law Journal, and Corporate Counsel, as well as other sources of legal information.

For questions call 1-877-256-2472 or contact us at [email protected]